Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.

Renata Ferrarotto Luana Guimaraes de SousaLei FengFrank E MottGeorge BlumenscheinMehmet AltanDiana BellFlavia BoniniKaiyi LiMario L Marques-PiubelliEduardo A Dal LagoJason M Johnson Yoshitsugu MitaniMyrna GodoyAnna LeeMichael KupfermanEhab HannaBonnie S GlissonYasir Y ElaminAdel El-Naggar

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

The study reached its primary end point with ≥4 PRs in 28 evaluable patients (confirmed ORR of 18%). The potential added benefit of avelumab to axitinib in ACC requires further investigation.

Keyphrases

phase ii
clinical trial
open label
end stage renal disease
newly diagnosed
squamous cell carcinoma
small cell lung cancer
chronic kidney disease
ejection fraction
double blind
prognostic factors
phase iii
patient reported outcomes
metastatic renal cell carcinoma
climate change
placebo controlled